Anti-CD19 CAR T-cell consolidation therapy combined with CD19(+) feeding T cells and TKI for Ph(+) acute lymphoblastic leukemia

We conducted a single-arm, open-label, single-center phase 1 study to assess the safety and efficacy of multicycle-sequential anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in combination with autologous CD19(+) feeding T cells (FTCs) and tyrosine kinase inhibitor (TKI) as consolidation th...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Li-Yun, Gong, Wen-Jie, Li, Ming-Hao, Zhou, Hai-Xia, Xu, Ming-Zhu, Qian, Chong-Sheng, Kang, Li-Qing, Xu, Nan, Yu, Zhou, Qiao, Man, Zhang, Tong-Tong, Zhang, Ling, Tian, Zheng-Long, Sun, Ai-Ning, Yu, Lei, Wu, De-Pei, Xue, Sheng-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463198/
https://www.ncbi.nlm.nih.gov/pubmed/36897251
http://dx.doi.org/10.1182/bloodadvances.2022009072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463198/
https://www.ncbi.nlm.nih.gov/pubmed/36897251
http://dx.doi.org/10.1182/bloodadvances.2022009072

Ejemplares similares